Roche’s Genentech Licenses Alector’s Brain-Penetrant Parkinson’s Therapy in $1.27 B Deal

Genentech, the Roche subsidiary, has signed an exclusive worldwide licensing agreement with Alector to develop, manufacture and commercialize AL050, an engineered glucocerebrosidase (GCase) enzyme-replacement therapy. The contract provides Alector with $100 million upfront and up to $1.17 billion in milestone payments, plus tiered royalties on future sales. Under the terms, Genentech assumes all development, regulatory, manufacturing and commercialization responsibilities, while Alector retains ownership of its blood-brain-barrier (BBB) delivery platform.

BioSpaceRoche licenses Parkinson's therapy for up to $1.27 billion

Alector, founded in 2013 by co-founder Arnon Rosenthal, originally pursued an immune-neurology strategy before refocusing on BBB delivery after a series of clinical setbacks. In 2021, the company partnered with GSK on two neurodegenerative antibodies, but GSK terminated the collaboration in July 2024 following a Phase 3 failure of latozinemab in frontotemporal dementia. Earlier, an AbbVie-partnered antibody, AL002, failed to slow Alzheimer’s progression in a mid-stage trial, prompting a 17 % layoff wave. The most recent restructuring reduced Alector’s workforce by 49 % (about 116 employees).

BioSpaceRoche licenses Parkinson's therapy for up to $1.27 billion

• Upfront payment: $100 million to Alector.

BioSpace

• Potential total value: up to $1.27 billion (including milestones and royalties).

BioSpace

• Cash runway: The deal extends Alector’s cash resources to at least 2029; the company previously reported $172.8 million on hand.

BioSpace

• Milestone triggers: Payments are tied to achievement of development, regulatory and sales targets for AL050.

Roche licenses Parkinson's therapy for up to $1.27 billion

AL050 pairs an engineered GCase enzyme with Alector’s proprietary “ABC” BBB carrier, which leverages the transferrin receptor to ferry the therapy across the BBB via endothelial cells. Alector claims preclinical studies demonstrated increased GCase activity and reduced toxic substrate accumulation in animal models of GBA-related Parkinson’s disease and Lewy body dementia. If successful, the therapy could address GCase deficiency—a recognized risk factor for Parkinson’s—potentially slowing disease progression. The agreement also aligns with Roche’s broader push into brain-penetrant technologies, complementing its own Brainshuttle platform and recent collaborations in oncology.

Roche licenses Parkinson's therapy for up to $1.27 billion BioSpace

• “The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain,” — Alector CEO Arnon Rosenthal — Alector CEO Arnon Rosenthal

BioSpace